

## Specialist Advisory Committees

Objective advice to Pharmac

[www.pharmac.govt.nz](http://www.pharmac.govt.nz)

## Cancer Treatments Advisory Committee Provisional recommendations 20 November 2025

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

### Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
<a href="#">Abemaciclib</a> for the adjuvant treatment of HR positive, HER2 negative early breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	High priority
<a href="#">Ribociclib</a> for the adjuvant treatment of HR positive, HER2 negative early breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	Medium priority
<a href="#">Olaparib</a> for the treatment of early high risk <i>BRCA</i> mutated HER2 negative breast cancer after neoadjuvant or adjuvant chemotherapy, within the context of treatments for malignancy, subject to special authority criteria.	High priority
<a href="#">Olaparib</a> for the treatment of HER2 negative germline <i>BRCA</i> mutated metastatic breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	Low priority
<a href="#">Olaparib</a> for the treatment of HER2 negative <i>PALB2</i> mutated metastatic breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	Decline
<a href="#">Belantamab mafodotin</a> for the treatment of relapsed or refractory multiple myeloma second line or later, within the context of treatments for malignancy, subject to Special Authority criteria.	High priority
<a href="#">Nivolumab</a> (with chemotherapy) in the neoadjuvant setting for people with resectable non-small cell lung cancer, within the context of treatments for malignancy, subject to special authority criteria.	High priority

[More information about the agenda items considered at the recent Cancer Treatments Advisory Committee meeting can be found on the Pharmac website.](#)